BioNTech (NASDAQ:BNTX) Raised to Buy at HSBC

HSBC upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a buy rating in a research note published on Friday, MarketBeat reports.

A number of other brokerages have also weighed in on BNTX. TD Cowen raised their price objective on BioNTech from $95.00 to $98.00 and gave the company a hold rating in a report on Tuesday, May 7th. HC Wainwright restated a buy rating and set a $113.00 price target on shares of BioNTech in a research report on Thursday, August 1st. Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They issued an inline rating and a $100.00 price objective for the company. Finally, BMO Capital Markets decreased their target price on shares of BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $110.40.

BioNTech Price Performance

Shares of BNTX stock traded up $0.90 on Friday, reaching $79.26. 459,925 shares of the company were exchanged, compared to its average volume of 699,586. BioNTech has a 1 year low of $76.53 and a 1 year high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The business has a 50-day moving average price of $87.74 and a 200 day moving average price of $90.63. The company has a market cap of $18.84 billion, a price-to-earnings ratio of 158.14 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. BioNTech’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.86) earnings per share. Equities research analysts forecast that BioNTech will post -2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. raised its position in BioNTech by 27.1% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 6,611 shares of the company’s stock valued at $698,000 after purchasing an additional 1,411 shares during the period. DAVENPORT & Co LLC acquired a new position in BioNTech in the fourth quarter valued at about $1,204,000. UMB Bank n.a. purchased a new position in BioNTech during the fourth quarter worth about $50,000. DekaBank Deutsche Girozentrale increased its position in shares of BioNTech by 43.1% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock valued at $44,610,000 after acquiring an additional 127,951 shares during the last quarter. Finally, LA Financiere DE L Echiquier raised its stake in shares of BioNTech by 18.7% in the 4th quarter. LA Financiere DE L Echiquier now owns 171,598 shares of the company’s stock valued at $18,110,000 after acquiring an additional 27,035 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.